Randomized phase II study of axitinib versus physicians best alternative choice of therapy in patients with recurrent glioblastoma
Crossref DOI link: https://doi.org/10.1007/s11060-016-2092-2
Published Online: 2016-03-02
Published Print: 2016-05
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Duerinck, J.
Du Four, S.
Vandervorst, F.
D’Haene, N.
Le Mercier, M.
Michotte, A.
Van Binst, A. M.
Everaert, H.
Salmon, I.
Bouttens, F.
Verschaeve, V.
Neyns, B.
Text and Data Mining valid from 2016-03-02